Routine Health Screening Market: By Test Type (Blood Glucose Test, Kidney Function Test, Bone Profile Test, Electrolyte Test, Liver Function Test, Lipid Profile Test, and Others), By Sample Type (Blood, Urine, Serum, Saliva, and Others), By Sample Collection Sites (Hospitals, Homes, Diagnostic Laboratories, Offices, and Others), and Geography

Routine Health Screening Market size was valued at USD 55.8 billion in 2023 and is projected to reach USD 87.6 billion by 2030 at a CAGR of 6.6% from 2024 to 2030. Health screening is vital for detecting diseases at an early stage. These tests are commonly used in preventive medicine to assess whether individuals show early signs of risk factors for conditions such as cancer, diabetes, high cholesterol, high blood pressure, and osteoporosis. These screenings are typically recommended based on age, gender, family history, and lifestyle factors to identify potential health risks before symptoms appear. Early identification of health issues allows for timely intervention, potentially reducing the severity of conditions and improving outcomes. Market expansion is driven by higher rates of chronic illnesses, increased funding from governments for population-wide medical screening programs, and the uptake of telemedicine and home-based services.

The introduction of telemedicine in healthcare has boosted the home-based testing market, while digital connectivity in the healthcare system has strengthened the health check-up market during the COVID-19 pandemic. The increasing prevalence of life-threatening diseases, including asymptomatic stages of non-communicable diseases like diabetes, hypertension, cancer, and cardiovascular diseases, is a key industry driver. For instance, over 30% of the U.S. population has prehypertension, increasing the risk of developing high blood pressure. Regular health check-ups help manage conditions effectively, yet only 1 in 4 U.S. adults have their hypertension controlled. However, Key restraints of the routine health screening market include high costs limiting access, the potential for overdiagnosis and false positives causing unnecessary procedures, and challenges in patient compliance and awareness regarding preventive healthcare benefits.

Routine Health Screening Market Recent Developments of the Market:

• In May 2023, the Indian Health Ministry launched a medical screening initiative for people with hypertension and diabetes. This initiative provides standard care to around 75 million people suffering from non-communicable diseases by 2025.
• In November 2023, Universal DX announced a strategic partnership with Quest Diagnostics, a U.S.-based supplier of diagnostic information services, to improve colorectal cancer screening in the U.S. Under the commercial agreement, Quest intends to perform and provide clinical laboratory services to providers and patients in the U.S. based on UDX’s Signal-C, an advanced colorectal cancer screening blood test.